Journal article
Does prescribing apixaban or rivaroxaban versus warfarin for patients diagnosed with atrial fibrillation save health system costs? A multivalued treatment effects analysis
Abstract
BackgroundNon-valvular atrial fibrillation (AF) is a common heart arrhythmia in the elderly population. AF patients are at high-risk of ischemic strokes, but oral anticoagulant (OAC) therapy reduces such risks. Warfarin had been the standard OAC for AF patients, however its effectiveness is highly variable and dependent on close monitoring of the anticoagulant response. Newer OACs such as rivaroxaban and apixaban address these drawbacks but are …
Authors
Situ M; Schwarz UI; Zou G; McArthur E; Kim RB; Garg AX; Sarma S
Journal
The European Journal of Health Economics, Vol. 25, No. 3, pp. 397–409
Publisher
Springer Nature
Publication Date
April 2024
DOI
10.1007/s10198-023-01594-7
ISSN
1618-7598